BMS, AbbVie get Priority Review for elotuzumab

Bristol-Myers Squibb Co. (NYSE:BMY) and AbbVie Inc. (NYSE:ABBV) said FDA accepted and granted Priority Review to a BLA for elotuzumab ( BMS-901608) in combination with other therapies as a second-line treatment for multiple myeloma (MM). BMS spokesperson Audrey Abernathy said the PDUFA date is Feb. 29, 2016.

BMS and AbbVie are co-developing the candidate. BMS, which is to lead elotuzumab's commercialization, intends to market the compound as Empliciti. The humanized mAb targeting SLAM family member 7 ( SLAMF7; CS1) has breakthrough therapy designation from FDA and Orphan Drug designation in the U.S. and EU to treat MM. ...